The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Summary: Background : Colorectal cancer in primary sclerosing cholangitis patients with ulcerative colitis is mostly right‐sided where concentrations of carcinogenic secondary bile acids are highest. Aim : To investigate whether ursodeoxycholic acid could be chemopreventive for colorectal cancer. Methods : A historical cohort study was performed on primary sclerosing cholangitis patients with ulcerative colitis where the 28 patients (cases) who were treated with ursodeoxycholic acid for at least 6 months (mean 3.4 ± 2.7 years) were compared with the 92 patients (controls) who were not treated with ursodeoxycholic acid. The primary outcomes were colorectal cancer and dysplasia. The secondary outcome was overall mortality. Results : The cumulative incidence of dysplasia or cancer was not significantly different between cases and controls (P = 0.17 by log‐rank test). The adjusted relative risk for cases of developing dysplasia or cancer was 0.59 (95% CI 0.26–1.36). The cumulative mortality was significantly different between groups (P = 0.02 by log‐rank test). The adjusted relative risk for cases of death was 0.44 (95% CI 0.22–0.90). Conclusion : In ulcerative colitis patients with primary sclerosing cholangitis, ursodeoxycholic acid did not reduce the risk of developing cancer or dysplasia. However, ursodeoxycholic acid may reduce mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ursodiol for Primary Sclerosing Cholangitis
Lindor, K. D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199703063361003 · Cited by 598
High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis
Harnois, D. M., Angulo, P., Jorgensen, R. A., LaRusso, N. F., & Lindor, K. D. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03777.x · Cited by 242
Cited by
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
“A historical cohort study compared 28 PSC patients under UDCA treatment with UC to 92 PSC patients with UC not treated with UDCA [120] and found a trend towards a lower risk of colonic dysplasia and neoplasia under UDCA treatment (adjusted relative risk 0.”
MethodDiagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R., Fevery, J., Kalloo, A., Nagorney, D. M., Boberg, K. M., Shneider, B., & Gores, G. J. (2010) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,224
Cairns, S. R., Scholefield, J. H., Steele, R. J., Dunlop, M. G., Thomas, H. J. W., Evans, G. D., Eaden, J. A., Rutter, M. D., Atkin, W. P., Saunders, B. P., et al. (2010) · Gut · doi:10.1136/gut.2009.179804 · Cited by 1,141
Extraintestinal Manifestations of Inflammatory Bowel Disease
Vavricka, S. R., Schoepfer, A., Scharl, M., Lakatos, P. L., Navarini, A., & Rogler, G. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000392 · Cited by 909
Farraye, F. A., Odze, R. D., Eaden, J., & Itzkowitz, S. H. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.035 · Cited by 494
Metadata
- Authors
- WOLF, J. M., RYBICKI, L. A., & LASHNER, B. A.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2005-10-14
- Volume
- 22
- Issue
- 9
- Pages
- 783-788
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W1998384426
- Cited by
- 130
- References
- 2
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. https://app.cochat.ai/papers/10.1111/j.1365-2036.2005.02650.x
- The paper
- WOLF, J. M., RYBICKI, L. A., & LASHNER, B. A. (2005). The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2005.02650.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.